(Q38191835)

30 August 2017

1 reference

title

Systemic lupus erythematosus: a therapeutic challenge for the XXI century (English)

1 reference

systemic lupus erythematosus

30 August 2017

1 reference

1 reference

Manuel Francisco Ugarte Gil

inferred from title

author

series ordinal

1

object named as

Manuel F Ugarte-Gil

1 reference

30 August 2017

2

Graciela S Alarcón

1 reference

PubMed ID

24577816

30 August 2017

language of work or name

1 reference

28 February 2014

1 reference

30 August 2017

Clinical Rheumatology

1 reference

30 August 2017

33

1 reference

30 August 2017

4

1 reference

30 August 2017

441-450

1 reference

Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus

30 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Predictors of survival in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA) XXXII: [corrected] contributions of admixture and socioeconomic status to renal involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Glucocorticoid use and abuse in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Cyclophosphamide: new approaches for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Current and novel therapeutics in the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Leflunomide: friend or foe for systemic lupus erythematosus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Systemic lupus erythematosus clinical trials-an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Sphingosine-1-phosphate and immune regulation: trafficking and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Efalizumab in the treatment of discoid lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-014-2531-4

Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study

21 January 2018

1 reference

12 December 2020

Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus

1 reference

12 December 2020

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

1 reference

12 December 2020

Prolonged remission in systemic lupus erythematosus

1 reference

12 December 2020

Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.

1 reference

12 December 2020

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

1 reference

12 December 2020

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture

1 reference

12 December 2020

Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial

1 reference

12 December 2020

FTY720-induced conversion of conventional Foxp3- CD4+ T cells to Foxp3+ regulatory T cells in NOD mice

1 reference

12 December 2020

Poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups

1 reference

12 December 2020

Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog

1 reference

12 December 2020

Cyclosporine (CsA) in lupus nephritis: assessing the evidence

1 reference

12 December 2020

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

12 December 2020

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

1 reference

12 December 2020

Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the LUMINA cohort (LXII): use of the SF-6D.

1 reference

12 December 2020

Long-term maintenance therapy with azathioprine in systemic lupus erythematosus

1 reference

12 December 2020

10.1007/S10067-014-2531-4

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24577816